In the Claims:

The current status of all claims is listed below and supercedes all previous lists of claims.

Please amend claims 12, 14, 16, 21, and 23 as follows:

1-11. (canceled).

12. (currently amended) A vaccine composition comprising a peptide sequence comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1) or a fragment thereof.

13. (previously presented) A vaccine composition as claimed in claim 12, in which the peptide is conjugated to a carrier protein.

14. (currently amended) A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide; wherein the peptide comprises an N-terminal portion of an angiotensin-II type-1 receptor comprising the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1), a conservative mutant thereof, or an active fragment thereof comprising at least five amino acid residues.

15. (previously presented) The method of claim 14 wherein the active fragment is a hexapeptide, heptapeptide, octapeptide, nonapeptide, or decapeptide.

16. (currently amended) The method of claim 14 wherein the peptide comprises the sequence EDGIKRIQDD (SEQ ID NO:2), a conservative mutant thereof, or an active fragment thereof comprising at least five amino acid residues.

17. (previously presented) The method of claim 16 wherein the conservative mutant comprises any one or more of the following amino acid substitutions: position 1 is E, D or Q, position 2 is D or E, position 3 is G or A, position 4 is I or A, position 5 is K or R, position 6 is R or K, position 7 is I or A, position 8 is Q or N, and position 9 and 10, independently, are each either D or E.

18. (previously presented) The method of claim 14 wherein the monoclonal antibody is humanized.

19. (previously presented) The method of claim 14 wherein the monoclonal antibody is 6313/G2 produced by the hybridoma cell line designated by accession number 93072117.

20. (previously presented) The method of claim 14 wherein the cancer is prostate cancer or breast cancer.

21. (currently amended) A method of treating a disease or condition associated with vascular smooth muscle cell proliferation comprising administering to a subject in need thereof a therapeutically effective amount of a monoclonal antibody, or a fragment thereof, that binds to a peptide; wherein the peptide comprises an N-terminal portion of an angiotensin-II type-1 receptor comprising the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG (SEQ ID NO:1), a conservative mutant thereof, or an active fragment thereof comprising at least five amino acid residues.

22. (previously presented) The method of claim 21 wherein the active fragment is a hexapeptide, heptapeptide, octapeptide, nonapeptide, or decapeptide.

23. (currently amended) The method of claim 21 wherein the peptide comprises the sequence EDGIKRIQDD (SEQ ID NO:2), a conservative mutant thereof, or an active fragment thereof comprising at least five amino acid residues.

24. (previously presented) The method of claim 23 wherein the conservative mutant comprises any one or more of the following amino acid substitutions: position 1 is E, D or Q, position 2 is D or E, position 3 is G or A, position 4 is I or A, position 5 is K or R, position 6 is R or K, position 7 is I or A, position 8 is Q or N, and position 9 and 10, independently, are each either D or E.

25. (previously presented) The method of claim 21 wherein the monoclonal antibody is humanized.

26. (previously presented) The method of claim 21 wherein the monoclonal antibody is 6313/G2 produced by the hybridoma cell line designated by accession number 93072117.

27. (previously presented) The method of claim 21 wherein the disease or condition is atherosclerosis.

28. (previously presented) The composition of claim 12 further comprising an adjuvant.